Key Insights

Highlights

Success Rate

83% trial completion

Published Results

173 trials with published results (21%)

Research Maturity

410 completed trials (51% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

10.5%

85 terminated out of 811 trials

Success Rate

82.8%

-3.7% vs benchmark

Late-Stage Pipeline

11%

90 trials in Phase 3/4

Results Transparency

42%

173 of 410 completed with results

Key Signals

173 with results83% success85 terminated

Data Visualizations

Phase Distribution

591Total
Not Applicable (203)
Early P 1 (14)
P 1 (136)
P 2 (148)
P 3 (66)
P 4 (24)

Trial Status

Completed410
Recruiting133
Terminated85
Unknown61
Active Not Recruiting53
Withdrawn30

Trial Success Rate

82.8%

Benchmark: 86.6%

Based on 410 completed trials

Clinical Trials (811)

Showing 20 of 20 trials
NCT03937817Recruiting

Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

NCT06251843CompletedPrimary

Support Strategies for Parents During the First Year Following Their Child's Diagnosis of Sickle Cell Disorder

NCT07648043Phase 1Not Yet RecruitingPrimary

Feasibility and Acceptability of Amani

NCT03049475CompletedPrimary

Pathophysiology of Acute Pain in Patients With Sickle Cell Disease

NCT07753681Recruiting

Domestication and Implementation of the PEN-Plus Clinical Model in the Zambian Health System

NCT07224360Phase 2RecruitingPrimary

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

NCT07656415Phase 3RecruitingPrimary

A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

NCT04691323Not ApplicableCompletedPrimary

The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.

NCT04688411Not ApplicableCompletedPrimary

An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease

NCT06725550Not ApplicableActive Not RecruitingPrimary

Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0

NCT06511453Not ApplicableActive Not RecruitingPrimary

Acupressure in Patients With Sickle Cell Disease

NCT05045820Not ApplicableActive Not RecruitingPrimary

Integrative Medicine in Pain Management in Sickle Cell Disease

NCT00047996Enrolling By InvitationPrimary

Blood Collection for Research Related to Certain Diseases Involving Blood Vessels

NCT05384756Phase 1Active Not RecruitingPrimary

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

NCT07187973Phase 1RecruitingPrimary

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

NCT07599176Phase 1RecruitingPrimary

Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

NCT06975865Phase 3RecruitingPrimary

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

NCT02447874Phase 1RecruitingPrimary

Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

NCT06155500Phase 1Active Not RecruitingPrimary

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

NCT00542230Recruiting

Blood Sampling for Research Related to Sickle Cell Disease

Scroll to load more

Research Network

Activity Timeline